Imunon, Inc. Files 8-K for Amendments and Financials
Ticker: IMNN · Form: 8-K · Filed: Mar 18, 2024 · CIK: 749647
Sentiment: neutral
Topics: corporate-filing, amendment, financials
TL;DR
Imunon filed an 8-K on 3/15/24 for corporate changes and financials.
AI Summary
On March 15, 2024, Imunon, Inc. filed an 8-K report detailing amendments to its Articles of Incorporation and financial statements. The company, formerly known as Celsion Corp, is incorporated in Delaware and has its principal business address in Lawrenceville, NJ.
Why It Matters
This filing provides updated corporate information and financial statements, which are crucial for investors to assess the company's current status and performance.
Risk Assessment
Risk Level: low — The filing is a routine corporate disclosure and does not indicate any immediate financial distress or significant operational changes.
Key Players & Entities
- Imunon, Inc. (company) — Registrant
- Celsion Corp (company) — Former company name
- Delaware (jurisdiction) — State of incorporation
- Lawrenceville, NJ (location) — Business address
- March 15, 2024 (date) — Date of earliest event reported
FAQ
What specific amendments were made to Imunon, Inc.'s Articles of Incorporation?
The filing indicates amendments to the Articles of Incorporation but does not specify the exact nature of these amendments in the provided text.
When was Imunon, Inc. formerly known as Celsion Corp?
The company was formerly known as Celsion Corp, with a date of name change noted as November 21, 2007.
What is the principal business address of Imunon, Inc.?
The principal business address is 997 Lenox Drive, Suite 100, Lawrenceville, NJ 08648.
What is the SEC file number for Imunon, Inc.?
The SEC file number for Imunon, Inc. is 001-15911.
What is the fiscal year end for Imunon, Inc.?
The fiscal year end for Imunon, Inc. is December 31.
Filing Stats: 558 words · 2 min read · ~2 pages · Grade level 11.9 · Accepted 2024-03-18 08:00:26
Key Financial Figures
- $0.01 — ch registered Common stock, par value $0.01 per share IMNN Nasdaq Capital Mark
Filing Documents
- form8-k.htm (8-K) — 42KB
- ex3-1.htm (EX-3.1) — 134KB
- 0001493152-24-010195.txt ( ) — 377KB
- imnn-20240315.xsd (EX-101.SCH) — 3KB
- imnn-20240315_lab.xml (EX-101.LAB) — 33KB
- imnn-20240315_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IMUNON INC. Dated: March 18, 2024 By: /s/ Jeffrey W. Church Jeffrey W. Church Executive Vice President and Chief Financial Officer